ProCE Banner Activity


Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life


This activity, Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life, will provide hematologists and oncologists with important information on the role of risk stratification in guiding treatment selection, efficacy and safety data for current and emerging myelofibrosis therapies, and strategies for integrating these agents into clinical practice in a way that prolongs survival, minimizes adverse events, and improves patient quality-of-life.

Welcome and Introductions
Personalized Treatment Selection for Myelofibrosis
Improving Patient Quality-of-Life
Q&A Session and Activity Roundup

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: September 22, 2022

Expiration: September 22, 2023

No longer available for credit.



John Mascarenhas

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Ruben Mesa

Ruben Mesa, MD, FACP

Executive Director
Mays Cancer Center at UT Health San Antonio MD Anderson
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, TX

Provided by

Jointly provided by the Potomac Center for Medical Education and Rockpointe 

ProCE Banner
ProCE Banner


This program is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

The intended audience for this educational initiative includes hematologists and oncologists, the clinicians responsible for the diagnosis and treatment of patients with myelofibrosis.

Learning Objectives

At the conclusion of this education, participants should be able to:

  • Use guideline recommended scoring systems to develop risk-informed treatment plans for patients with myelofibrosis

  • Integrate the latest clinical trial evidence into the selection and sequencing of treatments for patients with advanced myelofibrosis

  • Develop strategies to improve patient quality of life by minimizing disease symptoms and treatment-related toxicities

  • Communicate with patients regarding their disease, symptoms, and treatment options


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Faculty, Authors, and Content Developers
The faculty, authors, and content developers reported the following relevant financial relationships with ineligible companies:

John Mascarenhas, MD: Consulting Fee: Abbvie, BMS, Celgene, Constellation, CTI Bio, Galecto, Geron, Imago, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia, Novartis, Roche, Sierra Onc; Contracted Research: Abbive, BMS, Celgene, CTI Bio, Geron, Incyte, Kartos, Merck, Novartis, PharmaEssential, Roche

Ruben A. Mesa, MD, FACP: Consulting Fee: Abbvie, Bluprint Onc, BMS, CTI Bio, Genentech Incyte, Novartis, Sierra Onc; Contracted Research: Abbvie, Bluprint Onc, BMS, CTI, Incyte, Morphosys, PharmaEssentia

Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies: 

Chelsey Goins, PhD: Has no relevant financial relationships

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies: 
Katie Propst, PhD: Has no relevant financial relationships

Instructions for Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Disclosure of Unlabeled Use

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC credit or the evaluation, please email


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.